2024. Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s313. DOI:https://doi.org/10.25251/skin.8.supp.313.